Pharmactive enters a Nutra meets pharma initiative with mental health and metabolic balance formulations
Spanish Company, Pharmactive Biotech, S.L., is tapping into the pharmaceutical market with its leading branded ingredients, such as affron® saffron extract, for supporting mental health. The company has appointed Paul Clayton, PhD as Chair of its scientific advisory board. Together with Pharmactive’s medical advisor, Carlos Galmarini, MD, PhD, they will lead this strategic move for Pharmactive.
Affron® is a premium saffron ingredient standardized to 3.5% Lepticrosalides®, by HPLC, a complex of bioactive compounds responsible for the beneficial properties and organoleptic properties of affron®. It is backed by 6 human clinical studies that have shown to improve mood in healthy consumers with occasional stress and anxiety, and to improve sleeplessness.
The following main mechanisms of action of affron® have been identified:
“Including high-level medical and natural science experts on the advisory board enables the company to combine and reconciliate the two worlds of pharma and nutraceuticals, to benefit both consumers and medical practitioners and will help the pharmaceutical business provide greater value to their patrons,” says Jean-Marie Raymond, CEO at Pharmactive.
Paul Clayton is a clinical pharmacologist and pharmacological nutritionist. He is the former Chair of the Forum on Food & Health (UK) and a former Senior Scientific Advisor to the UK government’s Committee on the Safety of Medicines. Carlos Galmarini is the Founder and CEO of Topazium Smart Medicine, a biomedical and pharmaceutical artificial intelligence platform based in Madrid, Spain.